Split History
ETFs Holding CFRX »    CFRX Historical Stock Prices »
Video: What is a Stock Split?

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
ContraFect is a clinical-stage biotechnology company focused on the discovery and development of direct lytic agent, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Co.'s primary clinical candidate, exebacase, is an investigational lysin that targets Staphylococcus aureus. Co. has developed a variant of exebacase, known as CF-296, which provides an additional opportunity to develop a potential targeted therapy for deep-seated, invasive biofilm-associated Staph aureus infections. Co. is conducting further in vitro and in vivo characterization of CF-296 to evaluate the full profile of this compound. According to our CFRX split history records, ContraFect has had 1 split.
CFRX split history picture
ContraFect (CFRX) has 1 split in our CFRX split history database. The split for CFRX took place on February 04, 2020. This was a 1 for 10 reverse split, meaning for each 10 shares of CFRX owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split.

When a company such as ContraFect conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the CFRX split history from start to finish, an original position size of 1000 shares would have turned into 100 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into ContraFect shares, starting with a $10,000 purchase of CFRX, presented on a split-history-adjusted basis factoring in the complete CFRX split history. CFRX split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 09/12/2014
End date: 02/25/2021
Start price/share: $52.10
End price/share: $5.33
Dividends collected/share: $0.00
Total return: -89.77%
Average Annual Total Return: -29.74%
Starting investment: $10,000.00
Ending investment: $1,022.57
Years: 6.46
Date Ratio
02/04/20201 for 10
CFRX is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

CGIX Split History
CGNT Split History
CHDX Split History
CHE Split History
CHFS Split History
CHRS Split History
CLBS Split History
CLDN Split History
CLDX Split History
CLRB Split History

Also explore: CFRX shares outstanding history

China SXT Pharmaceuticals, Inc. (SXTC)
VYNE Therapeutics Inc. (VYNE)
The Sherwin-Williams Company (SHW)
Horizons US Marijuana Index ETF (HMUS)
MicroSectors FANG+ ETNs due January 8, 2038 (FNGS)
MicroSectors FANG+ Index 2X Leveraged ETNs due January 8, 2038 (FNGO)
MicroSectors FANG+ Index 3X Leveraged ETNs due January 8, 2038 (FNGU)
Moleculin Biotech, Inc. (MBRX)
Exela Technologies, Inc. (XELA)
eXp World Holdings, Inc. (EXPI)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

CFRX Insider Buying

CFRX Split History | www.SplitHistory.com | Copyright © 2013 - 2021, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.